Antares Pharma, Inc. (AIS) Announces the Issuance of a New Patent on VIBEX™ Device Platform  
4/16/2013 10:56:16 AM

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patent number 8,419,686 which relates to the device-injection site contacting interface. The interface design is applicable to the entire Antares VIBEX™ injector device platform. Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, “This is another example of the importance of our intellectual property strategy as we continue to actively protect the enhanced device technologies being applied to both established and new drugs. Over the past fifteen months, Antares has filed 30 patent applications and has received 8 new patents including this most recent issuance.” Dr. Wotton continued, “This patent focuses on the interface between injection devices and the patient. It demonstrates that Antares understands that self-injection requires unique device features for the home setting where a growing number of injectables are being used.”